strongbridge
biopharma
plc
host
third
quarter
financial
results
conference
call
october
dublin
ireland
trevose
globe
newswire
strongbridge
biopharma
plc
nasdaq
sbbp
global
biopharmaceutical
company
focused
development
commercialization
therapies
rare
diseases
significant
unmet
needs
today
announced
host
conference
call
members
strongbridge
management
team
thursday
october
et
discuss
company
third
quarter
financial
results
provide
business
update
conference
call
follow
anticipated
release
company
financial
results
earlier
day
event
details
strongbridge
host
conference
call
thursday
october
et
access
live
call
dial
domestic
international
conference
id
conference
call
also
audio
webcast
company
website
investor
webcasts
presentations
section
replay
call
made
available
one
week
following
conference
call
hear
replay
call
dial
domestic
international
conference
id
strongbridge
biopharma
strongbridge
biopharma
global
biopharmaceutical
company
focused
development
commercialization
therapies
rare
diseases
significant
unmet
needs
strongbridge
rare
endocrine
franchise
includes
levoketoconazole
cortisol
synthesis
inhibitor
currently
studied
phase
clinical
studies
treatment
endogenous
cushing
syndrome
veldoreotide
extended
release
somatostatin
analog
investigated
treatment
acromegaly
potential
additional
applications
conditions
amenable
somatostatin
receptor
activation
recorlev
veldoreotide
received
orphan
drug
designation
fda
european
medicines
agency
company
rare
neuromuscular
franchise
includes
dichlorphenamide
first
treatment
hyperkalemic
hypokalemic
related
variants
primary
periodic
paralysis
keveyis
orphan
drug
exclusivity
united
states
contacts
corporate
media
relations
elixir
health
public
relations
lindsay
rocco
lrocco
investor
relations
solebury
trout
mike
biega
mbiega
